期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 27, 期 7, 页码 851-866出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2017.1313231
关键词
Alzheimer's disease; amyloid beta protein; amyloid precursor protein; gamma secretase; gamma secretase inhibitor; Notch; cancer
资金
- National Natural Science Foundation of China [81402851, 81573281]
- Fundamental Research Funds for the Central Universities [2015ZD009]
Introduction: Gamma secretase (GS) is an intricate and multi-subunits complex, and it can cut various transmembrane proteins. Now it is a therapeutic target for a number of diseases. However, due to some side effects, the clinical development of GSI is not successful. Therefore, searching for effective GSIs has become a key point in drug discovery. Areas covered: This review discusses the structure and function of GS and various types of GSIs. And this article seeks to give an overview of the patents or applications published from 2013 to 2015 in which novel chemical classes are claimed to inhibit the GS. Expert opinion: Firstly, further understanding the structure and function of GS to elucidate the disease mechanism and develop AD therapies is urgent. Secondly, if the bioequivalence, pharmacokinetics and selectivity can be improved greatly, some failed clinical inhibitors still can become the promising compounds for clinical trials. Thirdly, some weaknesses are exposed during the development of GSI, especially the insufficient potency, low brain penetration and poor selectivity. Finally, to find potent and selective GSI is the major direction in future. Moreover, to find new indications and dosing regimens in a trial of GSIs also can be seen as new ways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据